Skip to main content
OpenTrials

Clinical trial condition

Neoplasms by Histologic Type

Explore clinical trials studying Neoplasms by Histologic Type. Study availability and eligibility vary by location and protocol.

30,134 public trials 6,478 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms by Histologic Type trial results

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • The University of Arizona Cancer Center - North Campus Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine Irvine, California, United States
View all 290 locations
View Trial Details
Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698

Conditions
Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +12 more
Locations
  • University of California Los Angeles Los Angeles, California, United States
  • Orlando Health Orlando, Florida, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
  • St. Elizabeth Healthcare Edgewood, Kentucky, United States
View all 35 locations
View Trial Details
Recruiting

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07480356

Conditions
Bladder (Urothelial, Transitional Cell) Cancer, Carcinoma, Carcinoma in Situ, +16 more
Locations
  • East Valley Urology Center of Arizona Queen Creek, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • Michael Oefelein Clinical Trials Bakersfield, California, United States
  • Renown Regional Medical Center St Louis, Missouri, United States
View Trial Details
Recruiting

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 50 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details

Related conditions